Tyrothricin contains about 20% gramicidin and 80% tyrocidine and belongs to the family of polypeptide antibiotics. It is active against a variety of gram-positive bacteria, including Streptococcus pneumoniae, Streptococcus pyogenes, Staphylococcus aureus and bacteria causing diphtheria.
Indication: Used in the treatment of local infections; mainly infections of the mouth, throat and superficial skin wounds.
Application: Formulated alone or as a combination drug product used in lozenges and topicals.
Product grades |
Non-sterile | ||
Compliance |
Ph. Eur. (Due to Tyrothricin monograph removal from US Pharmacopoeia, USP grade Tyrothricin product is no longer available.) |
||
Manufacturing site |
Xellia Pharmaceuticals Ltd., Budapest, Hungary |
||
Release site |
Xellia Pharmaceuticals Ltd., Budapest, Hungary |
||
Site registered |
EU GMP issued by Hungarian National Institute of Pharmacy recognized by FDA from March 1st 2018 according to Mutual Recognition Agreement (MRA) |
||
Regulatory documentation |
EU Drug Master File (DMF)/Certificate of Suitability (CEP) DMF also available in other selected countries outside EU |
||
Packaging sizes |
|
||
Packaging material |
|
||
Shelf life |
| ||
Storage conditions |
| ||
